ID   WERI-Rb-1
AC   CVCL_1792
AS   CVCL_2757
SY   WERI-RB-1; WERI-Rb 1; WERI-Rb1; WERI-RB1; WERI Rb-1; WERIRb1; WERI; Wills Eye Research Institute-Retinoblastoma-1
DR   CLO; CLO_0009583
DR   CLO; CLO_0009584
DR   CLO; CLO_0051563
DR   EFO; EFO_0005715
DR   CLDB; cl4695
DR   AddexBio; C0029002/4899
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ATCC; HTB-169
DR   BioSample; SAMN03472730
DR   cancercelllines; CVCL_1792
DR   CCRID; 3101HUMTCHu213
DR   Cell_Model_Passport; SIDM01414
DR   CLS; 300632
DR   Cosmic; 688119
DR   Cosmic; 909782
DR   DepMap; ACH-001421
DR   DSMZ; ACC-90
DR   DSMZCellDive; ACC-90
DR   ECACC; 06070602
DR   ENCODE; ENCBS087YAE
DR   ENCODE; ENCBS270AAA
DR   ENCODE; ENCBS282DQM
DR   ENCODE; ENCBS283KOW
DR   ENCODE; ENCBS283WND
DR   ENCODE; ENCBS679NMZ
DR   GEO; GSM749679
DR   GEO; GSM749766
DR   GEO; GSM749768
DR   GEO; GSM824870
DR   GEO; GSM945263
DR   GEO; GSM945318
DR   GEO; GSM1486290
DR   GEO; GSM2043881
DR   IGRhCellID; WERIRb1
DR   IZSLER; BS TCL 231
DR   JCRB; JCRB3028
DR   JCRB; KURB2683
DR   Lonza; 1147
DR   PRIDE; PXD030924
DR   Progenetix; CVCL_1792
DR   RCB; RCB2146
DR   TKG; TKG 0601
DR   Wikidata; Q54993776
RX   DOI=10.5795/jjscc.24.451;
RX   PubMed=679190;
RX   PubMed=844036;
RX   PubMed=1682862;
RX   PubMed=2751270;
RX   PubMed=6351622;
RX   PubMed=7499444;
RX   PubMed=7689221;
RX   PubMed=19686387;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=23498719;
RX   PubMed=25326674;
RX   PubMed=27115612;
RX   PubMed=28713896;
RX   PubMed=29192327;
RX   PubMed=30584916;
RX   PubMed=31781967;
RX   PubMed=32123578;
RX   PubMed=35409416;
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/WERI-Rb-1_Stam_protocol.pdf
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: ENCODE project common cell types; tier 3.
CC   Population: Caucasian.
CC   Doubling time: 96 hours (PubMed=844036); 50 hours (PubMed=25326674); 84 hours (PubMed=31781967); ~49 hours (DSMZ=ACC-90).
CC   Sequence variation: Gene deletion; HGNC; 9884; RB1; Zygosity=Homozygous (PubMed=25326674).
CC   Omics: CTCF ChIP-seq epigenome analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: JCRB; KURB2683; probable.
CC   Derived from site: In situ; Eye, globe; UBERON=UBERON_0010230.
ST   Source(s): ATCC; DepMap; DSMZ; JCRB; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 10 (TKG)
ST   CSF1PO: 10,12,13 (ATCC; DepMap; DSMZ; RCB)
ST   CSF1PO: 11,12 (JCRB)
ST   D13S317: 14
ST   D16S539: 13
ST   D18S51: 13,19
ST   D19S433: 14,15
ST   D21S11: 29
ST   D2S1338: 12,15
ST   D3S1358: 14,15
ST   D5S818: 11,12
ST   D7S820: 10,12,13 (JCRB)
ST   D7S820: 10,13 (ATCC; DepMap; DSMZ; RCB; TKG)
ST   D8S1179: 12,15
ST   FGA: 21
ST   Penta D: 12,13
ST   Penta E: 7,11
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C7541; Retinoblastoma
DI   ORDO; Orphanet_790; Retinoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   1Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 35
//
RX   DOI=10.5795/jjscc.24.451;
RA   Tsumuraya M., Nakajima T., Terasaki T., Kodama T., Shimosato Y.,
RA   Higuchi H., Uei Y.;
RT   "Analysis of LDH isoenzyme patterns in cell lines of the small cell
RT   carcinoma (lung) and retinoblastoma.";
RL   Nihon Rinsho Saibo Gakkai Zasshi 24:451-456(1985).
//
RX   PubMed=679190;
RA   McFall R.C., Nagy R.M., Nagle B.T., McGreevy L.M.;
RT   "Scanning electron microscopic observation of two retinoblastoma cell
RT   lines.";
RL   Cancer Res. 38:2827-2835(1978).
//
RX   PubMed=844036;
RA   McFall R.C., Sery T.W., Makadon M.;
RT   "Characterization of a new continuous cell line derived from a human
RT   retinoblastoma.";
RL   Cancer Res. 37:1003-1010(1977).
//
RX   PubMed=1682862; DOI=10.1016/S0161-6420(91)32134-1;
RA   Chan H.S.L., Thorner P.S., Haddad G., Gallie B.L.;
RT   "Multidrug-resistant phenotype in retinoblastoma correlates with
RT   P-glycoprotein expression.";
RL   Ophthalmology 98:1425-1431(1991).
//
RX   PubMed=2751270;
RA   Chan H.S.L., Canton M.D., Gallie B.L.;
RT   "Chemosensitivity and multidrug resistance to antineoplastic drugs in
RT   retinoblastoma cell lines.";
RL   Anticancer Res. 9:469-474(1989).
//
RX   PubMed=6351622; DOI=10.1016/S0002-9394(14)77822-5;
RA   Ohashi Y., Sasabe T., Nishida T., Nishi Y., Higashi H.;
RT   "Hanganutziu-Deicher heterophile antigen in human retinoblastoma
RT   cells.";
RL   Am. J. Ophthalmol. 96:321-325(1983).
//
RX   PubMed=7499444; DOI=10.1007/BF01213319;
RA   Inomata M., Saijo N., Kawashima K., Kaneko A., Fujiwara Y.,
RA   Kunikane H., Tanaka Y.;
RT   "Induction of apoptosis in cultured retinoblastoma cells by the
RT   protein phosphatase inhibitor, okadaic acid.";
RL   J. Cancer Res. Clin. Oncol. 121:729-738(1995).
//
RX   PubMed=7689221; DOI=10.1073/pnas.90.16.7578;
RA   Godbout R., Squire J.A.;
RT   "Amplification of a DEAD box protein gene in retinoblastoma cell
RT   lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:7578-7582(1993).
//
RX   PubMed=19686387; DOI=10.1111/j.1471-4159.2009.06322.x;
RA   Glubrecht D.D., Kim J.-H., Russell L., Bamforth J.S., Godbout R.;
RT   "Differential CRX and OTX2 expression in human retina and
RT   retinoblastoma.";
RL   J. Neurochem. 111:250-263(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=23498719; DOI=10.1016/S1470-2045(13)70045-7;
RA   Rushlow D.E., Mol B.M., Kennett J.Y., Yee S., Pajovic S.,
RA   Theriault B.L., Prigoda-Lee N.L., Spencer C., Dimaras H., Corson T.W.,
RA   Pang R., Massey C., Godbout R., Jiang Z., Zacksenhaus E., Paton K.,
RA   Moll A.C., Houdayer C., Raizis A., Halliday W., Lam W.L.,
RA   Boutros P.C., Lohmann D.R., Dorsman J.C., Gallie B.L.;
RT   "Characterisation of retinoblastomas without RB1 mutations: genomic,
RT   gene expression, and clinical studies.";
RL   Lancet Oncol. 14:327-334(2013).
//
RX   PubMed=25326674; DOI=10.1007/s00418-014-1285-z;
RA   Busch M., Philippeit C., Weise A., Dunker N.;
RT   "Re-characterization of established human retinoblastoma cell lines.";
RL   Histochem. Cell Biol. 143:325-338(2015).
//
RX   PubMed=27115612; DOI=10.1371/journal.pone.0153323;
RA   Kooi I.E., Mol B.M., Massink M.P.G., de Jong M.C., de Graaf P.,
RA   van der Valk P., Meijers-Heijboer H., Kaspers G.J.L., Moll A.C.,
RA   te Riele H., Cloos J., Dorsman J.C.;
RT   "A meta-analysis of retinoblastoma copy numbers refines the list of
RT   possible driver genes involved in tumor progression.";
RL   PLoS ONE 11:E0153323-E0153323(2016).
//
RX   PubMed=28713896; DOI=10.3892/ijmm.2017.3058;
RA   Liu Y., Fan Z.-G., Li K., Deng F., Xiong Y.-F., Liang M.-X., Ge J.;
RT   "An optimized gene transfection system in WERI-Rb1 cells.";
RL   Int. J. Mol. Med. 40:801-813(2017).
//
RX   PubMed=29192327; DOI=10.3892/or.2017.6100;
RA   Busch M.A., Papior D., Stephan H., Dunker N.;
RT   "Characterization of etoposide- and cisplatin-chemoresistant
RT   retinoblastoma cell lines.";
RL   Oncol. Rep. 39:160-172(2018).
//
RX   PubMed=30584916; DOI=10.1016/j.yexcr.2018.12.018;
RA   Schwermer M., Hiber M., Dreesmann S., Rieb A., Theissen J., Herold T.,
RA   Schramm A., Temming P., Steenpass L.;
RT   "Comprehensive characterization of RB1 mutant and MYCN amplified
RT   retinoblastoma cell lines.";
RL   Exp. Cell Res. 375:92-99(2019).
//
RX   PubMed=31781967; DOI=10.1007/s00418-019-01832-1;
RA   Ravishankar H., Mangani A.S., Shankar M.B., Joshi M., Devasena T.,
RA   Parameswaran S., Subramaniam K.;
RT   "Characterization of NCC-RbC-51, an RB cell line isolated from a
RT   metastatic site.";
RL   Histochem. Cell Biol. 153:101-109(2020).
//
RX   PubMed=32123578; DOI=10.1038/s41420-020-0237-8;
RA   Aubry A., Yu T., Bremner R.;
RT   "Preclinical studies reveal MLN4924 is a promising new retinoblastoma
RT   therapy.";
RL   Cell Death Discov. 6:2.1-2.12(2020).
//
RX   PubMed=35409416; DOI=10.3390/ijms23074058;
RA   Kakkassery V., Gemoll T., Kraemer M.M., Sauer T., Tura A., Ranjbar M.,
RA   Grisanti S., Joachim S.C., Mergler S., Reinhard J.;
RT   "Protein profiling of WERI-RB1 and etoposide-resistant WERI-ETOR reveals
RT   new insights into topoisomerase inhibitor resistance in retinoblastoma.";
RL   Int. J. Mol. Sci. 23:4058.1-4058.14(2022).
//